The evidence that parathyroid extract acts directly on bone appears conclusive (1-3). Whether the extract exerts an effect on the kidney, however, has not been so convincingly answered. It has long been known that an increase in urinary phosphate follows the administration of parathyroid extract (4, 5), but the mechanism of the phosphaturia has not been clearly elucidated.
The evidence that parathyroid extract acts directly on bone appears conclusive (1) (2) (3) . Whether the extract exerts an effect on the kidney, however, has not been so convincingly answered. It has long been known that an increase in urinary phosphate follows the administration of parathyroid extract (4, 5) , but the mechanism of the phosphaturia has not been clearly elucidated.
Although the osteoclastic action of parathyroid hormone could effect an increase in urinary inorganic phosphate, it could not simultaneously produce the hypophosphatemia observed in patients with hyperparathyroidism. Inhibition by the hormone of the renal mechanism for conserving phosphate, on the other hand, would account for both a rise in urinary and a fall in plasma phosphate.
Our studies demonstrate that a depression of the maximal renal tubular reabsorptive capacity for phosphate follows the administration of parathyroid extract, although in normal subjects prolonged treatment is required before such an effect is demonstrable.
SUBJECTS AND METHODS
Forty studies were carried out in nine of the normal subjects, the three patients with post-thyroidectomy hypoparathyroidism and the hyperparathyroid male described in the previous paper (6) . The experimental procedures have been outlined (6 8 The following abbreviations will be employed: GFR, glomerular filtration rate; RPF, effective renal plasma flow; CG., inulin clearance; CPAH, para-amino-hippurate clearance; Tm, maximal renal tubular transport rate; PTH, parathyroid extract; Ca, calcium; P, inorganic phosphate.
effective as demonstrated by a rise in serum Ca in at least one subject. Dosage is expressed in U.S.P. units, as assayed by the manufacturer. When given intravenously the hormone was usually administered over a period of 4 to 8 minutes. For the more prolonged studies it was given subcutaneously at 6 to 12 hourly intervals, except where otherwise indicated.
To study the effects of PTH on TmP, buffered sodium phosphate, pH 7.40, was infused until conditions of renal tubular saturation were assured. Simultaneous with the intravenous administration of PTH a sustaining infusion was begun containing, in addition to inulin and PAH, an amount of sodium phosphate calculated to maintain as constant as possible the elevated plasma P level. Thus, observations of the influence of PTH on TmP were permitted without the possible interference of rapidly changing plasma levels.
RESULTS
Acute effects of intravenous parathyroid extract at endogenous levels of plasma P A rise in urinary phosphate occurred immediately following the intravenous administration of 200 to 1,000 units of PTH both to normal ( Figure  1 ) and to hypoparathyroid (Figure 2 ) subjects. A typical study in a normal subject is outlined in Table I , while data from studies in three normal subjects are summarized in Table II . In two of the normal individuals, C. H., and J. N., the rise in urinary P occurred as a result of an increase in filtered P, which in turn, was caused by an increase in GFR. Phosphate reabsorption was increased in one subject and unchanged in the other. In the third normal individual, E. E., the increase in excreted P could be accounted for by a decrease in tubular reabsorption of P (Table II) . No change in serum calcium was observed during the 2 to 4 hours following the administration of PTH. Flushing frequently followed the intravenous administration of PTH, and transient headache was an occasional complaint. A mild and brief tachycardia often occurred, but no changes in temperature or blood pressure were observed. There was 557 Acute effects of intravenous parathyroid extract under conditions of phosphate loading As was noted at endogenous plasma P levels, no constant change in renal tubular reabsorption of P resulted from the administration of PTH to subjects receiving P infusions (Table III) . If in the study summarized in Table III one selects two periods with comparable levels of plasma P, e.g., the 6th, before the administration of PTH, and the 7th, after PTH was given, one notes that after PTH the excretion of P is increased. The rise in urinary P is ascribable to an increase in filtered P, the reabsorbed P remaining unchanged. Similar findings were noted in nine studies in five normal subjects (Table IV) . The levels of TmP following the administration of PTH did not differ significantly from those seen prior to the administration of the hormone (Figure 3 (Table IV) . In almost all normal subjects the rise in GFR was adequate to account for the observed increase in P excretion.
In the hypoparathyroid subjects, on the other hand, the rise in urinary P which followed the administration of PTH resulted not only from an increase in filtered P, but from a striking diminution in the reabsorbed P as well (Table V) on one occasion (5/6/55) the TmP was reduced was induced in five nor-by parathyroid extract to the level observed in the Lsions and in two hypo-only patient with spontaneous hyperparathyroidthe administration of ism studied. The latter, a 72-year-old male with a tract over periods of 60 plasma Ca of 14.05 mg. per 100 ml. and a plasma )jects hypercalcemia, hy-P of 0.53 AM per ml. was found to have a TmP of increase in urinary rcal, 26 E*M per minute. e observed (Table VII) .
The effect of the prolonged administration of d of mild skeletal :pain, parathyroid extract on C1,, and on CPAH, in conIyuria, and constipation. trast to the results in the acute studies, was inconstant (Table X) lower B. C.'s plasma P and TmP without altering the level of plasma Ca. Hyperparathyroidism was induced in this subject by intermittent intravenous administration of extract. This was the only one of the prolonged studies reported in hypoparathyroid patients in which PTH was given by other than the subcutaneous route. D. F. and W. R., two normal subjects, received three successive daily infusions, each containing 1,500 units of extract, and each given intravenously over a sixhour period. No effect on plasma Ca or P or on TmP (measured 15 hours after the last infusion of PTH) was observed. In W. R., an equal auantity of the same lot of hormone given in repeated subcutaneous injections over a similar period produced marked hyperparathyroidism (Table VII) . DISCUSSION Two explanations have been offered for the increase in urinary phosphate usually observed following the administration of parathyroid extract. The evidence supporting these hypotheses, an increase in the load of phosphate filtered through the kidney, on the one hand, and a diminution in the tubular reabsorption of phosphate, on the other, has been summarized by Bartter (8) . The ' The fall in CI3 in this subject in the hyperparathyroid state was believed ascribable to mild congestive heart failure, a state known to be accompanied by a reduced GFR (7) . Digitalis, with which she had been treated for signs of failure noted one year previously, had been omitted prior to the administration of parathyroid extract rise in filtered phosphate has been ascribed to an increase in glomerular filtration rate, to a rise in plasma phosphate, or to both (9) (10) (11) . Indeed, the demonstration that phosphaturia follows the administration to animals of formalin-inactivated (as assayed by its effect on serum calcium) parathyroid extract has been interpreted as indicating that the observed increase in urinary phosphate is an artifact ascribable to some non-hormonal component of an exceedingly heterogeneous preparation (12) .
Our data indicate that the phosphaturia seen immediately following the intravenous administration of the extract to normal individuals is the result of an increase in GFR with a consequent Co"ti;u as infusion of hnuIi mnd buffered sodium phosphOte. No manifestations of hyperparathyroidism were observed in W. R. following the intravenous administration of 1500 units of extract over a sixhour period on each of three successive days. Whether the renal tubule and bone of the normal individual must be constantly exposed to the extract for an even more prolonged period of time before a change in TmP or in calcium metabolism is demonstrable remains to be answered.
The demonstration of an action of PTH on the kidney does not, of course, exclude an effect on bone. Indeed, only by invoking an action of the hormone at both sites can one satisfactorily explain the chemical aberrations characteristic of patients with hyperparathyroidism. It would appear reasonable, then, to assume that the secretion(s) of the parathyroid alters metabolic processes in bone, in kidney, and possibly even elsewhere. 
